 BEVERLY, Mass., Dec. 30, 2020 GLOBE NEWSWIRE -- LexaGene Holdings, Inc., TSX-V: LXG; OTCQB: LXXGF the Company, a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it has started a series of studies required by the FDA for Emergency Use Authorization EUA testing for its COVID-19 assay in a point-of-care POC environment using its fully automated MiQLabTM system. 